analyses of large administrative databases that describe the relevant populations may provide some of the evidence required to justify healthcare decision-makers increasing their funding strategies for COPD. Finally, presenters from a number of healthcare systems described the limitations of evidence on effectiveness from the viewpoint of healthcare payers, some of the tools used by decisionmakers to address these difficulties, and how healthcare payers decide on the therapies to be funded.
The papers in this supplement summarize the My thanks, as chairman of the workshop, are extended to presentations and discussions that took place during the all the participants, and to GlaxoSmithKline for the meeting, in the hope that sharing this information with a educational grant that made the meeting possible.
wider audience can help to raise the profile of COPD.
